Bioreg

Publikationen Originalartikel

After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries.

Pombo-Suarez M, Sanchez-Piedra C, Gómez-Reino J, Lauper K, Mongin D, Iannone F, Pavelka K, Nordström DC, Inanc N, Codreanu C, Hyrich KL, Choquette D, Strangfeld...

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‚JAK-pot‘ collaboration.

Lauper K., Iudici M., Mongin D. Bergstra S. A., Choquette D., Codreanu C., Cordtz R., De Cock D., Dreyer L., Elkayam O., Hauge E. M.,...

Januskinase Inhibitors to Treat Rheumatoid Arthritis: Real World Data Match Clinical Trial Results. An Evaluation by BioReg, the Austrian Registry for Biologicals, Biosimilars, and Targeted Synthetic DMARDS in the Treatment of Inflammatory Rheumatic Diseases; Rheumatology: Current research(Sunnyvale), Vol.11 Iss. 5,No1000288 2021

Leeb B.F., Spellitz P., Eichbauer-Sturm G., Herold M., Stetter M., Puchner R., Singer F., Fritsch-Stork R. Link zum PDF: Januskinase Inhibitors to Treat Rheumatoid Arthritis...

Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. 

Rintelen Bernhard, Zwerina Jochen, Herold Manfred, Singer Franz, Hitzelhammer Johann, Halder Wolfgang, Eichbauer-Sturm Gabriela, Puchner Rudolf, Stetter Miriam, Leeb Burkhard, BMC Musculoskelet Disord. 2016 Oct 3;17(1):412 ...